Long term follow-up of patients with parkinson’s disease who had administered of allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) in SB-PD-001 study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009836

Enrollment

Registered

2024-10-11

Start date

2023-09-14

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Biological/Vaccine, Stem Cell : 1) IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) 2) Main ingredients and quantities: A9-DPC -7.0X10^6 cells (Use 3.15X10^6 cell

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Persons who have participated in SB-PD-001 Study and received A9-DPC 2) Persons who have provided written informed consent for this long-term follow-up

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

Measure	Time frame
Review occurrence of adverse event of special interests (AESIs)	—

Secondary

Measure	Time frame
MDS-UPDRS Total Score (defined On/Off), part ? (defined On/Off), ? score	—

Countries

Korea, Republic of

Contacts

Public ContactYoungso Chung

Yonsei University Health System, Severance Hospital

youngdtt@yuhs.ac+82-2-2228-5286

Outcome results